Lundbeck Q3 2019 Financial Results

Onfi impacted negatively by introductions of generic clobazam * Declined 69% (70% in L.C.) to DKK 840 million in 9M 2019 Numerous generic tablets and oral suspensions launched from October 2018 Aggressive generic pricing I 1.000 800 Onfi sales (Quarterly DKKm) 150.000 -76% 100.000 Onfi demand (Quarterly - TRX) -80% 55 600 Generic versions have taken ~80% of volume since October 2018 400 200 50.000 Q3.17 Q3.18 Q3.19 Q3.18 Q3.19 Source: Symphony Health (cf. Bloomberg) Lundbeck

View entire presentation